Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q12923

UPID:
PTN13_HUMAN

ALTERNATIVE NAMES:
Fas-associated protein-tyrosine phosphatase 1; PTP-BAS; Protein-tyrosine phosphatase 1E; Protein-tyrosine phosphatase PTPL1

ALTERNATIVE UPACC:
Q12923; B2RTR0; Q15159; Q15263; Q15264; Q15265; Q15674; Q16826; Q8IWH7; Q9NYN9; Q9UDA8

BACKGROUND:
The protein Tyrosine-protein phosphatase non-receptor type 13, with alternative names such as Fas-associated protein-tyrosine phosphatase 1, PTP-BAS, and Protein-tyrosine phosphatase PTPL1, is pivotal in modulating cell death pathways. It serves as a negative regulator for FAS-induced apoptosis and NGFR-mediated pro-apoptotic signaling, and potentially modulates PI3K signaling by dephosphorylating PIK3R2.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tyrosine-protein phosphatase non-receptor type 13 offers a promising avenue for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.